Skip to search formSkip to main contentSkip to account menu

Glembatumumab

Known as: Immunoglobulin G2, Anti-(Human Transmembrane Glycoprotein NMB (HGFIN) Extracellular Domain) Human Monoclonal CR011 Heavy Chain (133-215')-Disulfide with Human Monoclonal CR011 Kappa Light Chain, Dimer (221-221'':222-222'':225-225'':228- 228'')-Tetrakis, Immunoglobulin, Anti-(Human Glycoprotein NMB Extracellular Domain) (Human Monoclonal CR011 Heavy Chain), Disulfide with Human Monoclonal CR011 Gamma-2 Kappa-Chain, Dimer 
A human monoclonal antibody against transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB). Glembatumumab binds to GPNMB on cancer… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
In this study, we report the synthesis and the photochemical behavior of a series of new "click-on" fluorescent probes designed… 
Review
2017
Review
2017
Abstract Oncogene-targeted therapy is a major component of precision oncology, and although patients with metastatic melanoma… 
2016
2016
Objectives: PolyC binding protein 1 (PCBP1) is a transcriptional regulator of human mu-opioid receptor (hMOR) gene in the CNS and… 
2016
2016
Glycoprotein non-metastatic melanoma B (GPNMB) is a transmembrane protein overexpressed in 30 - 40% of triple negative breast… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Despite numerous clinical trials to improve outcomes for… 
2013
2013
The neuromedin B receptor (NMB-R), a member of the mammalian bombesin receptor family, is frequently overexpressed in various… 
2011
2011
Nursing pre-registration curricula in the United Kingdom (UK) and Australia (Aust.) are underpinned by codes of conduct which… 
Highly Cited
2010
Highly Cited
2010
Glembatumumab vedotin (CR-011-vc-MMAE) is a mAb-drug conjugate being developed by Celldex Therapeutics Inc for the treatment of… 
1992
1992
Murine neuroblastoma (C-1300 NMB) and malignant melanoma (B16) cells were radiated in presence of radiopharmaceutics…